ICON Public (NASDAQ:ICLR) PT Raised to $349.00 at TD Cowen

ICON Public (NASDAQ:ICLR) had its price target hoisted by research analysts at TD Cowen from $343.00 to $349.00 in a research note issued on Friday, Benzinga reports. The firm currently has a “buy” rating on the medical research company’s stock. TD Cowen’s price target would suggest a potential upside of 13.20% from the stock’s previous close.

ICLR has been the topic of a number of other research reports. Truist Financial lifted their target price on ICON Public from $357.00 to $367.00 and gave the company a “buy” rating in a report on Friday, February 23rd. Robert W. Baird lifted their target price on ICON Public from $362.00 to $363.00 and gave the company an “outperform” rating in a report on Friday. Evercore ISI boosted their price objective on ICON Public from $325.00 to $350.00 and gave the stock an “outperform” rating in a research note on Friday, February 23rd. Mizuho restated a “buy” rating and set a $346.00 price objective on shares of ICON Public in a research note on Thursday, April 4th. Finally, Barclays boosted their price objective on ICON Public from $325.00 to $355.00 and gave the stock an “overweight” rating in a research note on Friday, February 23rd. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, ICON Public presently has a consensus rating of “Moderate Buy” and a consensus price target of $321.64.

ICON Public Price Performance

Shares of NASDAQ:ICLR opened at $308.31 on Friday. ICON Public has a 52 week low of $181.92 and a 52 week high of $344.77. The company has a market cap of $25.44 billion, a P/E ratio of 37.51, a P/E/G ratio of 1.42 and a beta of 1.15. The company has a quick ratio of 1.21, a current ratio of 1.21 and a debt-to-equity ratio of 0.36. The business has a fifty day simple moving average of $318.89 and a 200-day simple moving average of $283.09.

ICON Public (NASDAQ:ICLR) last issued its earnings results on Wednesday, February 21st. The medical research company reported $3.40 earnings per share for the quarter, beating analysts’ consensus estimates of $3.27 by $0.13. ICON Public had a return on equity of 11.70% and a net margin of 8.30%. The firm had revenue of $2.07 billion for the quarter, compared to analysts’ expectations of $2.08 billion. Equities research analysts forecast that ICON Public will post 14.4 EPS for the current year.

Institutional Trading of ICON Public

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Riverview Trust Co purchased a new stake in shares of ICON Public during the first quarter worth about $31,000. Steph & Co. increased its position in shares of ICON Public by 11.2% during the first quarter. Steph & Co. now owns 1,852 shares of the medical research company’s stock worth $622,000 after acquiring an additional 186 shares during the last quarter. GAMMA Investing LLC increased its position in shares of ICON Public by 22.5% during the first quarter. GAMMA Investing LLC now owns 174 shares of the medical research company’s stock worth $58,000 after acquiring an additional 32 shares during the last quarter. Livelsberger Financial Advisory purchased a new stake in shares of ICON Public during the fourth quarter worth about $29,000. Finally, State of Tennessee Treasury Department increased its position in shares of ICON Public by 4.9% during the fourth quarter. State of Tennessee Treasury Department now owns 155,797 shares of the medical research company’s stock worth $44,101,000 after acquiring an additional 7,270 shares during the last quarter. 95.61% of the stock is owned by hedge funds and other institutional investors.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.